Bolt Biotherapeutics (BOLT) Non-Current Deffered Revenue (2021 - 2026)

Bolt Biotherapeutics has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $1.4 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 55.66% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 55.66% YoY) and the FY2025 annual result came in at $1.5 million, down 57.35% from the prior year.
• Non-Current Deffered Revenue declined to $1.4 million in Q1 2026 per BOLT's latest filing, from $1.5 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $13.6 million in Q1 2022 and troughed at $1.4 million in Q1 2026.
• A 5-year average of $7.2 million and a median of $5.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deffered Revenue surged 48.78% in 2022, then slumped 62.37% in 2024.
• Over 5 years, Non-Current Deffered Revenue stood at $12.9 million in 2022, then retreated by 29.52% to $9.1 million in 2023, then sank by 60.25% to $3.6 million in 2024, then tumbled by 57.35% to $1.5 million in 2025, then declined by 12.44% to $1.4 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.4 million, $1.5 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.